Brief: Dyadic Receives $3 Million Grant To Develop Cost-Effective Monoclonal Antibodies For Rsv And Malaria Using C1 Platform Technology
21/11/2024 13:37
Nov 21 (Reuters) - Dyadic International Inc DYAI.O :
* DYADIC RECEIVES $3 MILLION GRANT TO DEVELOP COST-EFFECTIVE
MONOCLONAL ANTIBODIES FOR RSV AND MALARIA USING C1 PLATFORM
TECHNOLOGY
Source text: ID:nGNX7tXjN0
Further company coverage: DYAI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development